Adial Pharmaceuticals (ADIL) Insider Davidson Buys 1,923 Shares
Chief Development Officer Matt Davidson added to his stake in Adial Pharmaceuticals as part of a series of insider purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Matt Davidson, Chief Development Officer at Adial Pharmaceuticals, Inc. ($ADIL), bought 1,923 shares on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ADIL is down 12.8% after 1 week, down 5.0% after 1 month and up 17.1% to date (from the $2.98 close on Jun 11, 2026).
ADIL
Adial Pharmaceuticals, Inc.
Key Points
- Adial Pharmaceuticals Chief Development Officer Matt Davidson acquired 1,923 shares on June 11, 2026.
- The stock traded around $2.85 per share recently, sitting well below its 50-day moving average of $4.52.
- Alliance Global Partners initiated coverage on the stock with a buy rating and an $11.00 price target on August 3, 2026.
Get $ADIL trade alerts by text
We text you when insiders, Congress or big funds trade $ADIL. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Adial Pharmaceuticals, Inc. alert may contain errors. Disclosures
Matt Davidson Buys Shares of Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. (NasdaqCM: ADIL) saw insider activity when Chief Development Officer Matt Davidson acquired 1,923 shares on June 11, 2026. This trade adds context to how company leaders manage their holdings, especially as insiders navigate shifting share prices for the clinical-stage biotech firm.
Recent Insider Activity at Adial Pharmaceuticals
The transaction by Davidson joins a cluster of notable insider and institutional purchases in the same period. On June 12, 2026, Wendy Young bought 36,378 shares at a price of $2.75 each, totaling $100,039.50. On that same day, Matt Davidson also recorded another transaction for 232,417 shares. Later in the month, on June 29, 2026, Coastlands Capital LP acquired 25,000 shares valued at $65,000.
Stock Performance and Valuation Context
Adial Pharmaceuticals shares recently changed hands at $2.85. The equity has moved between a 52-week low of $1.31 and a 52-week high of $10.75. Its 50-day moving average rests at $4.52, while the 200-day moving average is tracked at $3.60. The company carries a market capitalization of roughly $12.9 million and a beta of 1.39, meaning the stock tends to swing more than the wider market.
Analysts Set New Price Targets
Wall Street firms have kept a close watch on the clinical-stage company. On August 3, 2026, Alliance Global Partners initiated coverage on the stock with a buy rating and an $11.00 price target. Across the broader analyst community, the stock holds a consensus recommendation from three opinions, with price targets ranging from a low of $6.00 to a high of $11.00.
About Adial Pharmaceuticals
Adial Pharmaceuticals focuses on creating treatments and preventions for addiction and related disorders. Its main product candidate is AD04, a serotonin-3 antagonist currently studied in Phase 3 clinical trials to treat alcohol use disorder. The company also works on non-opioid pain reduction candidates.
What to Watch at Adial Pharmaceuticals, Inc.
Investors will look toward the company's next earnings report, scheduled for August 11, 2025, to gauge clinical progress and financial health. Observers should also keep track of future SEC filings to see if insiders continue adjusting their positions.
Related Filing Alerts
Source: Matt Davidson's Form 4 filing on $ADIL (Jun 11, 2026). Find the original filing: ADIL Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts